GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kinnate Biopharma Inc (NAS:KNTE) » Definitions » 14-Day RSI

Kinnate Biopharma (Kinnate Biopharma) 14-Day RSI : 62.58 (As of May. 20, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Kinnate Biopharma 14-Day RSI?

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.

As of today (2024-05-20), Kinnate Biopharma's 14-Day RSI is 62.58.

The industry rank for Kinnate Biopharma's 14-Day RSI or its related term are showing as below:

KNTE's 14-Day RSI is not ranked
in the Biotechnology industry.
Industry Median: 48.37 vs KNTE: 62.58

Competitive Comparison of Kinnate Biopharma's 14-Day RSI

For the Biotechnology subindustry, Kinnate Biopharma's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kinnate Biopharma's 14-Day RSI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kinnate Biopharma's 14-Day RSI distribution charts can be found below:

* The bar in red indicates where Kinnate Biopharma's 14-Day RSI falls into.



Kinnate Biopharma  (NAS:KNTE) 14-Day RSI Calculation

The formula for calculating RSI is:

RSI=100[ 100 / ( 1 + Average Gain / Average Loss )]

* Note that the formula uses a positive value for the average loss.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Kinnate Biopharma  (NAS:KNTE) 14-Day RSI Explanation

The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.

Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.

RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.


Kinnate Biopharma 14-Day RSI Related Terms

Thank you for viewing the detailed overview of Kinnate Biopharma's 14-Day RSI provided by GuruFocus.com. Please click on the following links to see related term pages.


Kinnate Biopharma (Kinnate Biopharma) Business Description

Traded in Other Exchanges
N/A
Address
103 Montgomery Street, Suite 150, The Presidio of San Francisco, San Francisco, CA, USA, 94129
Kinnate Biopharma Inc is a clinical-stage precision oncology company focused on the discovery, design, and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers. The company's pipeline product candidates are; exarafenib (KIN-2787), which is a Rapidly Accelerated Fibrosarcoma (RAF) inhibitor in development for the treatment of patients with lung cancer, melanoma, and other solid tumors, and KIN-3248, a Fibroblast Growth Factor Receptors (FGFR) inhibitor, designed for the treatment of patients with intrahepatic cholangiocarcinoma (ICC), a cancer of the bile ducts in the liver, and urothelial carcinoma (UC), a cancer of the bladder lining, as well as other solid tumors.
Executives
James B. Tananbaum director, 10 percent owner 3052 PACIFIC AVENUE, SAN FRANCISCO CA 94115
Foresite Capital Fund Iv, L.p. 10 percent owner 600 MONTGOMERY STREET, SUITE 4500, SAN FRANCISCO CA 94111
Orbimed Advisors Llc director 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Carl L Gordon director 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Jill Desimone director C/O PRAXIS PRECISION MEDICINES, INC., 99 HIGH STREET, 30TH FLOOR, BOSTON MA 02110
Orbimed Asia Gp Iv, L.p. director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK, NY 10022
Orbimed Advisors Iv Ltd director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Capital Gp Viii Llc director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022-4629
Richard Thomas Williams officer: Chief Medical Officer C/O KINNATE BIOPHARMA INC., 11975 EL CAMINO REAL, SUITE 101, SAN DIEGO CA 92130
Orbimed Capital Gp Vii Llc director 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Capital Llc director 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Genesis Gp Llc director 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Helen Sabzevari director 20374 SENECA MEADOWS PARKWAY, GERMANTOWN MD 20876
Neha Krishnamohan officer: Chief Financial Officer 12707 HIGH BLUFF DRIVE, SAN DIEGO CA 92130
Dean J Mitchell director C/O BRISTOL MYERS SQUIBB CO, 345 PARK AVE, NEW YORK NY 10164

Kinnate Biopharma (Kinnate Biopharma) Headlines

From GuruFocus

Kinnate Biopharma Inc. to Participate in Upcoming Investor Conferences

By GuruFocusNews GuruFocusNews 06-21-2022